REFERENCES
4. Varela Barca L, Vidal-Bonnet L, Fariñas MC, et al. Analysis of sex differences in the clinical presentation, management and prognosis of infective endocarditis in Spain. Heart 2021;107:1717-24.
5. Baddour LM, Shafiyi A, Lahr BD, et al. A contemporary population-based profile of infective endocarditis using the expanded rochester epidemiology project. Mayo Clin Proc 2021;96:1438-45.
6. Naidoo NS, Ponnusamy S, Naidoo DP. A 10-year retrospective analysis of the clinical profile and outcomes of infective endocarditis at a tertiary hospital in KwaZulu-Natal, South Africa. Cardiovasc J Afr 2022;33:194-9.
7. Nienaber CA, Clough RE, Sakalihasan N, et al. Aortic dissection. Nat Rev Dis Primers 2016;2:16053.
8. Fernández-Hidalgo N, Almirante B, Tornos P, et al. Immediate and long-term outcome of left-sided infective endocarditis. a 12-year prospective study from a contemporary cohort in a referral hospital. Clin Microbiol Infect 2012;18:E522-30.
9. Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009;169:463-73.
10. Fernández-Hidalgo N, Ribera A, Larrosa MN, et al. Impact of staphylococcus aureus phenotype and genotype on the clinical characteristics and outcome of infective endocarditis. a multicentre, longitudinal, prospective, observational study. Clin Microbiol Infect 2018;24:985-91.
11. Escolà-Vergé L, Fernández-Hidalgo N, Larrosa MN, Fernandez-Galera R, Almirante B. Secular trends in the epidemiology and clinical characteristics of Enterococcus faecalis infective endocarditis at a referral center (2007-2018). Eur J Clin Microbiol Infect Dis 2021;40:1137-48.
12. Fernández-Hidalgo N, Almirante B, Tornos P, et al. Prognosis of left-sided infective endocarditis in patients transferred to a tertiary-care hospital-prospective analysis of referral bias and influence of inadequate antimicrobial treatment. Clin Microbiol Infect 2011;17:769-75.
13. Botelho-Nevers E, Thuny F, Casalta JP, et al. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med 2009;169:1290-8.
14. Cambridge dictionary. Available from: https://dictionary.cambridge.org [Last accessed on 25 May 2023].
15. Tattevin P, Watt G, Revest M, Arvieux C, Fournier PE. Update on blood culture-negative endocarditis. Med Mal Infect 2015;45:1-8.
16. Ferrera C, Vilacosta I, Fernández C, et al. Reassessment of blood culture-negative endocarditis: its profile is similar to that of blood culture-positive endocarditis. Rev Esp Cardiol 2012;65:891-900.
17. Lamas CC, Fournier PE, Zappa M, et al. Diagnosis of blood culture-negative endocarditis and clinical comparison between blood culture-negative and blood culture-positive cases. Infection 2016;44:459-66.
18. Díez-Villanueva P, Muñoz P, Marín M, et al. Infective endocarditis: absence of microbiological diagnosis is an independent predictor of inhospital mortality. Int J Cardiol 2016;220:162-5.
19. Firiana L, Siswanto BB, Yonas E, Prakoso R, Pranata R. Factors affecting mortality in patients with blood-culture negative infective endocarditis. Int J Angiol 2020;29:12-8.
20. Suardi LR, de Alarcón A, García MV, et al. Blood culture-negative infective endocarditis: a worse outcome? Infect Dis 2021;53:755-63.
21. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the european society of cardiology (ESC). endorsed by: european association for cardio-thoracic surgery (EACTS), the european association of nuclear medicine (EANM). Eur Heart J 2015;36:3075-128.
22. Pecoraro AJK, Pienaar C, Herbst PG, et al. Causes of infective endocarditis in the Western Cape, South Africa: a prospective cohort study using a set protocol for organism detection and central decision making by an endocarditis team. BMJ Open 2021;11:e053169.
23. Saby L, Laas O, Habib G, et al. Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. J Am Coll Cardiol 2013;61:2374-82.
24. Pizzi MN, Roque A, Fernández-Hidalgo N, et al. Improving the diagnosis of infective endocarditis in prosthetic valves and intracardiac devices with 18F-fluordeoxyglucose positron emission tomography/computed tomography angiography. Circulation 2015;132:1113-26.
25. Sarrazin JF, Philippon F, Tessier M, et al. Usefulness of fluorine-18 positron emission tomography/computed tomography for identification of cardiovascular implantable electronic device infections. J Am Coll Cardiol 2012;59:1616-25.
26. Graziosi M, Nanni C, Lorenzini M, et al. Role of 18F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study. Eur J Nucl Med Mol Imaging 2014;41:1617-23.
27. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation 2021;143:e72-e227.
28. Blomström-Lundqvist C, Traykov V, Erba PA, et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020;41:2012-32.
29. Wang TKM, Sánchez-Nadales A, Igbinomwanhia E, Cremer P, Griffin B, Xu B. Diagnosis of infective endocarditis by subtype using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography: a contemporary meta-analysis. Circ Cardiovasc Imaging 2020;13:e010600.
30. Juneau D, Golfam M, Hazra S, et al. Positron emission tomography and single-photon emission computed tomography imaging in the diagnosis of cardiac implantable electronic device infection: a systematic review and meta-analysis. Circ Cardiovasc Imaging 2017;10:e005772.
31. Scholtens AM, van Aarnhem EE, Budde RP. Effect of antibiotics on FDG-PET/CT imaging of prosthetic heart valve endocarditis. Eur Heart J Cardiovasc Imaging 2015;16:1223.
32. Auletta S, Varani M, Horvat R, Galli F, Signore A, Hess S. PET radiopharmaceuticals for specific bacteria imaging: a systematic review. J Clin Med 2019;8:197.
33. Cuervo G, Escrihuela-Vidal F, Gudiol C, Carratalà J. Current challenges in the management of infective endocarditis. Front Med 2021;8:641243.
34. Selton-Suty C, Célard M, Le Moing V, et al. Preeminence of staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis 2012;54:1230-9.
35. Habib G, Erba PA, Iung B, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J 2019;40:3222-32.
36. Tissot-Dupont H, Casalta JP, Gouriet F, et al. International experts’ practice in the antibiotic therapy of infective endocarditis is not following the guidelines. Clin Microbiol Infect 2017;23:736-9.
37. García de la Mària C, Cervera C, Pericàs JM, et al. Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration. PLoS One 2015;10:e0125818.
38. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011;204:340-7.
39. Aguado JM, San-Juan R, Lalueza A, et al. High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia. Emerg Infect Dis 2011;17:1099-102.
40. Lebeaux D, Fernández-Hidalgo N, Pilmis B, Tattevin P, Mainardi JL. Aminoglycosides for infective endocarditis: time to say goodbye? Clin Microbiol Infect 2020;26:723-8.
41. Thwaites GE, Scarborough M, Szubert A, et al. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:668-78.
42. Shrestha NK, Shah SY, Wang H, et al. Rifampin for surgically treated staphylococcal infective endocarditis: a propensity score-adjusted cohort study. Ann Thorac Surg 2016;101:2243-50.
43. Le Bot A, Lecomte R, Gazeau P, et al. Is rifampin use associated with better outcome in staphylococcal prosthetic valve endocarditis? Clin Infect Dis 2021;72:e249-55.
44. Cheng MP, Lawandi A, Butler-Laporte G, De l'Étoile-Morel S, Paquette K, Lee TC. Adjunctive daptomycin in the treatment of methicillin-susceptible staphylococcus aureus Bacteremia: a randomized, controlled trial. Clin Infect Dis 2021;72:e196-203.
45. Pujol M, Miró JM, Shaw E, et al. Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial. Clin Infect Dis 2021;72:1517-25.
46. Tong SYC, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA 2020;323:527-37.
47. Tattevin P, Boutoille D, Vitrat V, et al. Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study. J Antimicrob Chemother 2014;69:2010-3.
48. Destache CJ, Guervil DJ, Kaye KS. Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience. Int J Antimicrob Agents 2019;53:644-9.
49. Pericàs JM, Moreno A, Almela M, et al. Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial. Clin Microbiol Infect 2018;24:673-6.
50. Lecomte R, Bourreau A, Deschanvres C, et al. Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible staphylococcus aureus infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study. Clin Microbiol Infect 2021;27:1015-21.
51. Henderson A, Harris P, Hartel G, et al. Benzylpenicillin versus flucloxacillin for penicillin-susceptible Staphylococcus aureus bloodstream infections from a large retrospective cohort study. Int J Antimicrob Agents 2019;54:491-5.
52. Aldman M, Kavyani R, Kahn F, Påhlman LI. Treatment outcome with penicillin G or cloxacillin in penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective cohort study. Int J Antimicrob Agents 2022;59:106567.
53. West KA, Sheeti A, Tamura MacKay K, Forrest GN. Eosinophilic syndromes associated with daptomycin use: re-exposure hypersensitivity pneumonitis and prior peripheral eosinophilia. Open Forum Infect Dis 2022;9:ofac065.
54. Turner RB, Wilson DE, Saedi-Kwon H, et al. Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline. J Antimicrob Chemother 2018;73:772-8.
55. Muñoz P, Kestler M, De Alarcon A, et al. Current epidemiology and outcome of infective endocarditis: a multicenter, prospective, cohort study. Medicine 2015;94:e1816.
56. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001;32:50-62.
57. Baddley JW, Benjamin DK Jr, Patel M, et al. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis 2008;27:519-29.
58. Arnold CJ, Johnson M, Bayer AS, et al. Candida infective endocarditis: an observational cohort study with a focus on therapy. Antimicrob Agents Chemother 2015;59:2365-73.
59. Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012;18 Suppl 7:19-37.
60. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 2016;62:e1-50.
61. Lefort A, Chartier L, Sendid B, et al. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect 2012;18:E99-E109.
62. Giuliano S, Guastalegname M, Russo A, et al. Candida endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian study of endocarditis. Expert Rev Anti Infect Ther 2017;15:807-18.
63. Hasse B, Hannan MM, Keller PM, et al. International society of cardiovascular infectious diseases guidelines for the diagnosis, treatment and prevention of disseminated mycobacterium chimaera infection following cardiac surgery with cardiopulmonary bypass. J Hosp Infect 2020;104:214-35.
64. Gasch O, Meije Y, Espasa M, Font B, Jiménez S, Fernández-Hidalgo N. Disseminated infection due to mycobacterium chimaera after aortic valve replacement. Rev Esp Cardiol 2019;72:502-3.
65. Julian KG, Crook T, Curley E, et al. Long-term follow-up of post-cardiac surgery Mycobacterium chimaera infections: A 5-center case series. J Infect 2020;80:197-203.
66. Forestier E, Roubaud-Baudron C, Fraisse T, et al. Comprehensive geriatric assessment in older patients suffering from infective endocarditis. A prospective multicentric cohort study. Clin Microbiol Infect 2019;25:1246-52.
67. Lacroix A, Revest M, Patrat-Delon S, et al. Outpatient parenteral antimicrobial therapy for infective endocarditis: a cost-effective strategy. Med Mal Infect 2014;44:327-30.
68. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation 2015;132:1435-86.
69. Andrews MM, von Reyn CF. Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis. Clin Infect Dis 2001;33:203-9.
70. Pericà S JM, Llopis J, González-Ramallo V, et al. Outpatient parenteral antibiotic treatment for infective endocarditis: a prospective cohort study from the GAMES cohort. Clin Infect Dis 2019;69:1690-700.
71. Gil-Navarro MV, Lopez-Cortes LE, Luque-Marquez R, Galvez-Acebal J, de Alarcon-Gonzalez A. Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis. J Clin Pharm Ther 2018;43:220-3.
72. Herrera-Hidalgo L, López-Cortes LE, Luque-Márquez R, et al. Ampicillin and ceftriaxone solution stability at different temperatures in outpatient parenteral antimicrobial therapy. Antimicrob Agents Chemother 2020:64.
73. Dahl A, Rasmussen RV, Bundgaard H, et al. Enterococcus faecalis infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome. Circulation 2013;127:1810-7.
74. Olaison L, Schadewitz K, Swedish Society of Infectious Diseases Quality Assurance Study Group for Endocarditis. Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used? Clin Infect Dis 2002;34:159-66.
75. Sullam PM, Täuber MG, Hackbarth CJ, Sande MA. Therapeutic efficacy of teicoplanin in experimental enterococcal endocarditis. Antimicrob Agents Chemother 1985;27:135-6.
76. Yao JD, Thauvin-Eliopoulos C, Eliopoulos GM, Moellering RC Jr. Efficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother 1990;34:827-30.
77. Nicolau DP, Marangos MN, Nightingale CH, et al. Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis. Antimicrob Agents Chemother 1996;40:55-60.
78. López P, Gavaldà J, Martin MT, et al. Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis. Antimicrob Agents Chemother 2001;45:1387-93.
79. Pavleas J, Skiada A, Daikos GL, et al. Efficacy of teicoplanin, administered in two different regimens, in the treatment of experimental endocarditis due to Enterococcus faecalis. J Chemother 2008;20:208-12.
80. De Nadaï T, François M, Sommet A, et al. Efficacy of teicoplanin monotherapy following initial standard therapy in Enterococcus faecalis infective endocarditis: a retrospective cohort study. Infection 2019;47:463-9.
81. Escolà-Vergé L, Fernández-Hidalgo N, Rodríguez-Pardo D, et al. Teicoplanin for treating enterococcal infective endocarditis: A retrospective observational study from a referral centre in Spain. Int J Antimicrob Agents 2019;53:165-70.
82. Gavaldà J, Len O, Miró JM, et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007;146:574-9.
83. Fernández-Hidalgo N, Almirante B, Gavaldà J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clin Infect Dis 2013;56:1261-8.
84. Pericàs JM, Cervera C, Moreno A, et al. Outcome of enterococcus faecalis infective endocarditis according to the length of antibiotic therapy: preliminary data from a cohort of 78 patients. PLoS One 2018;13:e0192387.
85. Ramos-Martínez A, Pericàs JM, Fernández-Cruz A, et al. Four weeks versus six weeks of ampicillin plus ceftriaxone in Enterococcus faecalis native valve endocarditis: a prospective cohort study. PLoS One 2020;15:e0237011.
86. Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med 2019;380:415-24.
87. Lemaignen A, Bernard L, Tattevin P, et al. Oral switch versus standard intravenous antibiotic therapy in left-sided endocarditis due to susceptible staphylococci, streptococci or enterococci (RODEO): a protocol for two open-label randomised controlled trials. BMJ Open 2020;10:e033540.
88. Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of vienna. Clin Infect Dis 2018;67:795-8.
